CURE’s cervical cancer page is an extensive resource of cancer information featuring the latest cervical cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on cervical cancer.
April 29th 2024
The Food and Drug Administration approved Tivdak for metastatic cervical cancer that progressed on or after chemotherapy.
Tivdak Confers 30% Reduction in Mortality Risk in Cervical Cancer
October 22nd 2023A 30% reduction in the risk of death versus. investigator’s choice of chemotherapy as second or third line therapy was concluded when Tivdak was combined for the treatment of recurrent or metastatic cervical cancer with disease progression on doublet chemotherapy.
Keytruda Plus Chemoradiotherapy Bests Standard of Care in Advanced Cervical Cancer
October 20th 2023Adding Keytruda to EBRT and chemotherapy, followed by brachytherapy, improved progression-free survival in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.
Cervical Cancer Survivor Donates Embryos to Fellow Survivor to Help Fulfill Dream of Motherhood
August 25th 2022Cervical cancer survivor Ginny Marable heard about a story of a fellow cervical cancer survivor, Tamika Felder, not being able to preserve her fertility. The story moved Marable so much that she and her husband donated their embryos to Felder.
Cancer Vaccine-Tecentriq Combo Elicits ‘Very Encouraging’ Outcomes in Advanced Cervical Cancer
May 10th 2022Treatment with an investigational cancer vaccine plus Tecentriq was associated with positive outcomes in patients with heavily pre-treated advanced cervical cancer, according to findings from an interim analysis of a phase 2 trial.
Imfinzi Fails to Improve Survival in Locally Advanced Cervical Cancer
March 25th 2022AstraZeneca, the manufacturer of the drug, announced that treatment with Imfinzi plus chemoradiotherapy did not improve survival compared with standard-of-care chemoradiotherapy alone in patients with locally advanced cervical cancer.
Novel Therapy May Address ‘High Unmet Clinical Need’ in Recurrent/Metastatic Cervical Cancer
April 28th 2021Treatment with tisotumab vedotin, a novel antibody-drug conjugate, in women with recurrent or metastatic cervical cancer, led to an objective response rate of 24% with a manageable safety profile.
FDA Approves Expanded Use of CINtec PLUS Cytology Test in Preventing Cervical Cancer
September 16th 2020The Food and Drug Administration approved the expanded use of the biomarker test CINtec PLUS Cytology that looks at HPV related biomarkers that could lead to cervical cancer. This is the first triage test approved in this space.